Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy

Molecular Therapy

Volumn 15, Issue 8, 2007, Pages 1423-1431

  Traas, Anne M ^a   Wang, Ping ^a   Ma, Xiucui ^b   Tittiger, Mindy ^b   Schaller, Laura ^b   O'donnell, Patricia ^a   Sleeper, Meg M ^a   Vite, Charles ^a   Herati, Ramin ^b   Aguirre, Gustavo D ^a   Haskins, Mark ^a   Ponder, Katherine P ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; COMPLEMENTARY DNA; LEVO IDURONIDASE; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; ARTHROPATHY; ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; DISEASE SEVERITY; DOG; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME RELEASE; FACE DYSMORPHIA; GENE EXPRESSION; GENE INSERTION; GENETIC TRANSDUCTION; HERNIA; HURLER SYNDROME; INCIDENCE; LIVER CELL; LONG TERMINAL REPEAT; NEWBORN; NONHUMAN; PROMOTER REGION; THORAX DEFORMITY; VALVULAR HEART DISEASE; VIRAL GENE THERAPY;

ANIMALS; ANIMALS, NEWBORN; BRAIN; DNA; DOGS; GENE THERAPY; GENETIC VECTORS; HUMANS; IDURONIDASE; LYSOSOMES; MUCOPOLYSACCHARIDOSIS I; NERVOUS SYSTEM DISEASES; RETROVIRIDAE; RNA;

CANIS FAMILIARIS;

EID: 34547101208     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300201     Document Type: Article

References (44)

1. Neufeld, EF and Muenzer, J (2001). The mucopolysaccharidoses. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle D (eds). Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill, New York. pp. 3421-3452.
2. Stoltzfus, LJ, Sosa-Pineda, B, Moskowitz, SM, Menon, KP, Dlott, B, Hooper, L et al. (1992). Cloning and characterization of cDNA encoding canine alpha-L-iduronidase. mRNA deficiency in mucopolysaccharidosis I dog. J Biol Chem 267: 6570-6575.
3. Menon, KP, Tieu, PT and Neufeld, EF (1992). Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I. Genomics 14: 763-768.
4. Field, RE, Buchanan, JA, Copplemans, MG and Aichroth, PM (1994). Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br 76: 975-981.
5. Guffon, N, Souillet, G, Maire, I, Straczek, J and Guibaud, P (1998). Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 133: 119-125.
6. Peters, C, Shapiro, EG, Anderson, J, Henslee-Downey, PJ, Klemperer, MR, Cowan, MJ et al. (1998). Hurler syndrome: II. outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The storage disease collaborative study group. Blood 91: 2601-2608.
7. Braunlin, EA, Stauffer, NR, Peters, CH, Bass, JL, Berry, JM, Hopwood, JJ et al. (2003). Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 92: 882-886.
8. Staba, SL, Escolar, ML, Poe, M, Kim, Y, Martin, PL, Szabolcs, P et al (2004). Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350: 1960-1969.
9. Ashworth, JL, Biswas, S, Wraith, E and Lloyd, IC (2006). Mucopolysaccharidoses and the eye. Surv Ophthalmol 51: 1-17.
10. Kakkis, ED, Muenzer, J, Tiller, GE, Waber, L, Belmont, J, Passage, M et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182-188.
11. Sifuentes, M, Doroshow, R, Hoft, R, Mason, G, Walot, I, Diament, M et al. (2007). A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90: 171-180.
12. Wraith, JE (2005). The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6: 489-506.
13. Braunlin, EA, Berry, JM and Whitley, CB (2006). Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98: 416-418.
14. Liu, Y, Xu, L, Hennig, AK, Kovacs, A, Fu, A, Chung, S et al. (2005). Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11: 35-47.
15. Chung, S, Ma, X, Liu, Y, Lee, D, Tittiger, M and Ponder, KP (2007). Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 90: 181-192.
16. Kobayashi, H, Carbonaro, D, Pepper, K, Petersen, D, Ge, S, Jackson, H et al. (2005). Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11: 776-789.
17. Hartung, SD, Frandsen, JL, Pan, D, Koniar, BL, Graupman, P, Gunther, R et al. (2004). Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9: 866-875.
18. Shull, RM, Lu, X, McEntee, MF, Bright, RM, Pepper, KA and Kohn, DB (1996). Myoblast gene therapy in canine mucopolysaccharidosis. I: abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther 7: 1595-1603.
19. Shull, R, Lu, X, Dube, I, Lutzko, C, Kruth, S, Abrams-Oqq, A et al (1996). Humoral immune response limits gene therapy in canine MPS I. Blood 88: 377-379.
20. Lutzko, C, Kruth, S, Abrams-Ogg, AC, Lau, K, Li, L, Clark, BR et al (1999). Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 93: 1895-1905.
21. Lutzko, C, Omori, F, Abrams-Oqq, AC, Shull R, Li L, Lau K et al. (1999). Gene therapy for canine alpha-L-iduronidase deficiency: In utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Hum Gene Ther 10: 1521-1532.
22. Meertens, L, Zhao, Y, Rosic-Kablar, S, Li, L, Chan, K, Dobson, H et al. (2002). In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: Infection of multiple tissues and neonatal gene expression. Hum Gene Ther 13: 1809-1820.
23. Ponder, KP, Wang, B, Wang, P, Ma, X, Herati, R, Wang, B et al. (2006). Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol Ther 14: 5-13.
24. Wang, B, O'Malley, TM, Xu, L, Vite, C, Wang, P, O'Donnell, PA et al (2006). Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab 87: 8-21.
25. Shull, RM, Munger, RJ, Spellacy, E, Hall, CW, Constantopoulos, G and Neufeld, EF (1982). Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I. Am J Pathol 109: 244-248.
26. Xu, L, Mango, RL, Sands, MS, Haskins, ME, Ellinwood, NM and Ponder, KP (2002). Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol Ther 6: 745-758.
27. Kakkis, E, McEntee, M, Vogler, C, Le, S, Levy, B, Belichenko, P et al (2004). Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83: 163-174.
28. Matte, U, Yogalingam, G, Brooks, D, Leistner, S, Schwartz, I, Lima, L et al. (2003). Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab 78: 37-43.
29. Kakkis, ED, McEntee, MF, Schmidtchen, A, Neufeld, EF, Ward, DA, Gompf, RE et al. (1996). Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156-167.
30. Shull, RM, Kakkis, ED, McEntee, MF, Kania, SA, Jonas, AJ and Neufeld, EF (1994). Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 91: 12937-12941.
31. Xu, L, Mei, M, Haskins, ME, Nichols, TC, O'donnell, P, Cullen, K et al. (2006). Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res Nov: (epub ahead of print).
32. Renteria, VG, Ferrans, VJ and Roberts, WC (1976). The heart in the Hurler syndrome: Gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol 38: 487-501.
33. Jordan, MC, Zheng, Y, Ryazantsev, S, Rozengurt, N, Roos, KP and Neufeld, EF (2005). Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol Genet Metab 86: 233-243.
34. Braunlin, E, Mackey-Bojack, S, Panoskaltsis-Mortari, A, Berry, JM, McElmurry, RT, Riddle, M et al. (2006). Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: Implications for assessment of therapeutic interventions in Hurler syndrome. Pediatr Res 59: 27-32.
35. Xu, L, Haskins, ME, Melniczek, JR, Gao, C, Weil, MA, O'Malley, TM et al. (2002). Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 5: 141-153.
36. Baum, C, Kustikova, O, Modlich, U, Li, Z and Fehse, B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263.
37. Vogler, C, Levy, B, Grubb, JH, Galvin, N, Tan, Y, Kakkis, E et al. (2005). Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102: 14777-14782.
38. Ma, X, Liu, Y, Tittiger, M, Hennig, A, Kovacs, A, Popelka, S et al (2007). Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 15: 889-902.
39. Ciron, C, Desmaris, N, Colle, MA, Raoul, S, Joussemet, B, Verot, L et al. (2006). Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 60: 204-213.
40. Ponder, KP, Melniczek, JR, Xu, L, Weil, MA, O'Malley, TM, O'Donnell, PA et al. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 99: 13102-13107.
41. Mango, RL, Xu, L, Sands, MS, Vogler, C, Seiler, G, Schwarz, T et al (2004). Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 82: 4-19.
42. Sleeper, MM, Fornasari, B, Ellinwood, NM, Weil, MA, Melniczek, J, O'Malley, TM et al. (2004). Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII. Circulation 110: 815-820.
43. Meikle, PJ, Grasby, DJ, Dean, CJ, Lang, DL, Bockmann, M, Whittle, AM et al. (2006). Newborn screening for lysosomal storage disorders. Mol Genet Metab 88: 307-314.
44. Wang, D, Eadala, B, Sadilek, M, Chamoles, NA, Turecek, F, Scott, CR et al. (2005). Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem 51: 898-900.